Search Medical Condition
Please enter condition
Please choose location

Harrison, New York Clinical Trials

A listing of Harrison, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (147) clinical trials

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

The study will be conducted at the University of Illinois at Chicago and New York Presbyterian Hospital-Westchester Division. Patients with schizophrenia or schizoaffective disorder who are considered by their clinicians to not be clinically stable, or to be stable but still symptomatic, will be referred to the study. After obtaining ...

Phase

3.5 miles

Learn More »

International Study to Predict Optimised Treatment - in Depression

This is an open-label, randomised (effectiveness) study (ie. comparison of active treatments) to identify genetic markers, brain function, brain structure, and psychological and cognitive indicators (or a combination of markers) in MDD subjects versus healthy controls. Approximately 2,016 subjects with major depressive disorder (MDD) across multiple international sites (USA, Canada, ...

Phase

3.5 miles

Learn More »

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

3.5 miles

Learn More »

A Study of Modified Stem Cells in Traumatic Brain Injury (TBI)

SB623 cells are adult bone-marrow-derived cells that are transiently transfected with a plasmid construct encoding the intracellular domain of human Notch-1. These cells produce trophic factors that protect neurons in models of ischemic insult. In a rat contusion model of TBI, implantation of SB623 around the area of the injury ...

Phase

3.5 miles

Learn More »

Efficacy Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Eligible participants for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD. This is a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of treatment. Approximately 470 participants will be enrolled at approximately 75 centers in North America. Study medication will ...

Phase

3.5 miles

Learn More »

Long Term Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Participant has successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, or 12-AVR-131. Participants will be enrolled in the study for approximately 56 weeks (participants who have a follow-up visit 3 months after the last dose of treatment will be enrolled for approximately 64 weeks). Approximately 700 participants will be enrolled at approximately 135 ...

Phase

3.5 miles

Learn More »

The WISE Trial - Walking Improvement for SCI With Exoskeleton

Community dwelling iSCI participants may improve clinical gait function by engaging in a gait training regimen, where robotic exoskeletons can readily deliver a precise dose and simultaneously reduce the physical stress imposed on therapists using conventional manually assisted stepping practice. Exoskeleton training is predicted to improve function in participants receiving ...

Phase N/A

3.5 miles

Learn More »